APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Linagliptin DPP-4 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Linagliptin DPP-4 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174007670323 December 2025193 pages

Choose your research edition.

Industry ResearchLinagliptin DPP-4 Inhibitors Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Linagliptin DPP-4 Inhibitors Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Linagliptin DPP-4 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Linagliptin DPP-4 Inhibitors Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Linagliptin DPP-4 Inhibitors Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Linagliptin DPP-4 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Linagliptin DPP-4 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Linagliptin DPP-4 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Linagliptin DPP-4 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Linagliptin DPP-4 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Linagliptin DPP-4 Inhibitors include Yangzijiang Pharmaceutical Group, Cspc Holdings Company, MINSHENG PHARMACEUTICAL, Shandong Lukang Pharmaceutical, Eli Lilly, Sichuan Kelun Pharmaceutical, China Resources Shuanghe Pharmaceutical, Huahai Pharmaceutical and Jiangsu Deyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Linagliptin DPP-4 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Linagliptin DPP-4 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Linagliptin DPP-4 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Linagliptin DPP-4 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Linagliptin DPP-4 Inhibitors Segment by Company

Yangzijiang Pharmaceutical Group

Cspc Holdings Company

MINSHENG PHARMACEUTICAL

Shandong Lukang Pharmaceutical

Eli Lilly

Sichuan Kelun Pharmaceutical

China Resources Shuanghe Pharmaceutical

Huahai Pharmaceutical

Jiangsu Deyuan Pharmaceutical

Chengda Pharmaceuticals

Zydus

Torrent Pharmaceuticals

Mankind Pharma

Boehringer Ingelheim

Alkem Labs

Linagliptin DPP-4 Inhibitors Segment by Type

Original Drug

Generic Drug

Linagliptin DPP-4 Inhibitors Segment by Application

Hospital

Retail Pharmacy

Linagliptin DPP-4 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Linagliptin DPP-4 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Linagliptin DPP-4 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Linagliptin DPP-4 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Linagliptin DPP-4 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Linagliptin DPP-4 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Linagliptin DPP-4 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Linagliptin DPP-4 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Linagliptin DPP-4 Inhibitors Industry Trends Table 2. Linagliptin DPP-4 Inhibitors Industry Drivers Table 3. Linagliptin DPP-4 Inhibitors Industry Opportunities and Challenges Table 4. Linagliptin DPP-4 Inhibitors Industry Restraints Table 5. Global Linagliptin DPP-4 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Linagliptin DPP-4 Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Manufacturers Table 9. Global Linagliptin DPP-4 Inhibitors Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Linagliptin DPP-4 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Linagliptin DPP-4 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Linagliptin DPP-4 Inhibitors Manufacturers, Product Type & Application Table 13. Global Linagliptin DPP-4 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Linagliptin DPP-4 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Original Drug Table 17. Major Manufacturers of Generic Drug Table 18. Global Linagliptin DPP-4 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2026) & (k units) Table 20. Global Linagliptin DPP-4 Inhibitors Sales by Type (2027-2032) & (k units) Table 21. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global Linagliptin DPP-4 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021-2026) & (k units) Table 25. Global Linagliptin DPP-4 Inhibitors Revenue by Type (2027-2032) & (k units) Table 26. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Retail Pharmacy Table 30. Global Linagliptin DPP-4 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2026) & (k units) Table 32. Global Linagliptin DPP-4 Inhibitors Sales by Application (2027-2032) & (k units) Table 33. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2026) Table 34. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2027-2032) Table 35. Global Linagliptin DPP-4 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021-2026) & (k units) Table 37. Global Linagliptin DPP-4 Inhibitors Revenue by Application (2027-2032) & (k units) Table 38. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2026) Table 39. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2027-2032) Table 40. Global Linagliptin DPP-4 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Linagliptin DPP-4 Inhibitors Sales by Region (2021-2026) & (k units) Table 42. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Region (2021-2026) Table 43. Global Linagliptin DPP-4 Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Linagliptin DPP-4 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 47. North America Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 48. Europe Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 50. Europe Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2027-2032) & (k units) Table 57. Global Linagliptin DPP-4 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Linagliptin DPP-4 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Linagliptin DPP-4 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region (2021-2026) Table 61. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region (2027-2032) Table 62. Yangzijiang Pharmaceutical Group Company Information Table 63. Yangzijiang Pharmaceutical Group Business Overview Table 64. Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Product Portfolio Table 66. Yangzijiang Pharmaceutical Group Recent Development Table 67. Cspc Holdings Company Company Information Table 68. Cspc Holdings Company Business Overview Table 69. Cspc Holdings Company Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Cspc Holdings Company Linagliptin DPP-4 Inhibitors Product Portfolio Table 71. Cspc Holdings Company Recent Development Table 72. MINSHENG PHARMACEUTICAL Company Information Table 73. MINSHENG PHARMACEUTICAL Business Overview Table 74. MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Product Portfolio Table 76. MINSHENG PHARMACEUTICAL Recent Development Table 77. Shandong Lukang Pharmaceutical Company Information Table 78. Shandong Lukang Pharmaceutical Business Overview Table 79. Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 81. Shandong Lukang Pharmaceutical Recent Development Table 82. Eli Lilly Company Information Table 83. Eli Lilly Business Overview Table 84. Eli Lilly Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Eli Lilly Linagliptin DPP-4 Inhibitors Product Portfolio Table 86. Eli Lilly Recent Development Table 87. Sichuan Kelun Pharmaceutical Company Information Table 88. Sichuan Kelun Pharmaceutical Business Overview Table 89. Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 91. Sichuan Kelun Pharmaceutical Recent Development Table 92. China Resources Shuanghe Pharmaceutical Company Information Table 93. China Resources Shuanghe Pharmaceutical Business Overview Table 94. China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 96. China Resources Shuanghe Pharmaceutical Recent Development Table 97. Huahai Pharmaceutical Company Information Table 98. Huahai Pharmaceutical Business Overview Table 99. Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 101. Huahai Pharmaceutical Recent Development Table 102. Jiangsu Deyuan Pharmaceutical Company Information Table 103. Jiangsu Deyuan Pharmaceutical Business Overview Table 104. Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio Table 106. Jiangsu Deyuan Pharmaceutical Recent Development Table 107. Chengda Pharmaceuticals Company Information Table 108. Chengda Pharmaceuticals Business Overview Table 109. Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio Table 111. Chengda Pharmaceuticals Recent Development Table 112. Zydus Company Information Table 113. Zydus Business Overview Table 114. Zydus Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Zydus Linagliptin DPP-4 Inhibitors Product Portfolio Table 116. Zydus Recent Development Table 117. Torrent Pharmaceuticals Company Information Table 118. Torrent Pharmaceuticals Business Overview Table 119. Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio Table 121. Torrent Pharmaceuticals Recent Development Table 122. Mankind Pharma Company Information Table 123. Mankind Pharma Business Overview Table 124. Mankind Pharma Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Mankind Pharma Linagliptin DPP-4 Inhibitors Product Portfolio Table 126. Mankind Pharma Recent Development Table 127. Boehringer Ingelheim Company Information Table 128. Boehringer Ingelheim Business Overview Table 129. Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Product Portfolio Table 131. Boehringer Ingelheim Recent Development Table 132. Alkem Labs Company Information Table 133. Alkem Labs Business Overview Table 134. Alkem Labs Linagliptin DPP-4 Inhibitors Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Alkem Labs Linagliptin DPP-4 Inhibitors Product Portfolio Table 136. Alkem Labs Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Linagliptin DPP-4 Inhibitors Distributors List Table 140. Linagliptin DPP-4 Inhibitors Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Linagliptin DPP-4 Inhibitors Product Image Figure 2. Global Linagliptin DPP-4 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Linagliptin DPP-4 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Linagliptin DPP-4 Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Linagliptin DPP-4 Inhibitors Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Linagliptin DPP-4 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Original Drug Image Figure 9. Generic Drug Image Figure 10. Global Linagliptin DPP-4 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Linagliptin DPP-4 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Linagliptin DPP-4 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Retail Pharmacy Image Figure 18. Global Linagliptin DPP-4 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Linagliptin DPP-4 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2032) Figure 21. Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Linagliptin DPP-4 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2032) Figure 24. North America Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 26. U.S. Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Germany Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 38. China Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales Market Share by Country (2021-2032) Figure 46. Brazil Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Linagliptin DPP-4 Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Linagliptin DPP-4 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Linagliptin DPP-4 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 57. North America Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Linagliptin DPP-4 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 59. Europe Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Linagliptin DPP-4 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Linagliptin DPP-4 Inhibitors Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Linagliptin DPP-4 Inhibitors Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Hospital
  • Retail Pharmacy
Companies covered
  • Yangzijiang Pharmaceutical Group
  • Cspc Holdings Company
  • MINSHENG PHARMACEUTICAL
  • Shandong Lukang Pharmaceutical
  • Eli Lilly
  • Sichuan Kelun Pharmaceutical
  • China Resources Shuanghe Pharmaceutical
  • Huahai Pharmaceutical
  • Jiangsu Deyuan Pharmaceutical
  • Chengda Pharmaceuticals
  • Zydus
  • Torrent Pharmaceuticals
  • Mankind Pharma
  • Boehringer Ingelheim
  • Alkem Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Linagliptin DPP-4 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Linagliptin DPP-4 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Linagliptin DPP-4 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Linagliptin DPP-4 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Linagliptin DPP-4 Inhibitors Market Dynamics
  1. 2.1 Linagliptin DPP-4 Inhibitors Industry Trends
  2. 2.2 Linagliptin DPP-4 Inhibitors Industry Drivers
  3. 2.3 Linagliptin DPP-4 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Linagliptin DPP-4 Inhibitors Industry Restraints
3 Linagliptin DPP-4 Inhibitors Market by Manufacturers
  1. 3.1 Global Linagliptin DPP-4 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Linagliptin DPP-4 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Linagliptin DPP-4 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Linagliptin DPP-4 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Linagliptin DPP-4 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Linagliptin DPP-4 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Linagliptin DPP-4 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Linagliptin DPP-4 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Linagliptin DPP-4 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Linagliptin DPP-4 Inhibitors Tier 1, Tier 2, and Tier 3
4 Linagliptin DPP-4 Inhibitors Market by Type
  1. 4.1 Linagliptin DPP-4 Inhibitors Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Linagliptin DPP-4 Inhibitors Sales by Type
  5. 4.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Linagliptin DPP-4 Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global Linagliptin DPP-4 Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global Linagliptin DPP-4 Inhibitors Revenue by Type
  9. 4.3.1 Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Linagliptin DPP-4 Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Type (2021-2032)
5 Linagliptin DPP-4 Inhibitors Market by Application
  1. 5.1 Linagliptin DPP-4 Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.2 Global Linagliptin DPP-4 Inhibitors Sales by Application
  5. 5.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Linagliptin DPP-4 Inhibitors Sales by Application (2021-2032)
  7. 5.2.3 Global Linagliptin DPP-4 Inhibitors Sales Market Share by Application (2021-2032)
  8. 5.3 Global Linagliptin DPP-4 Inhibitors Revenue by Application
  9. 5.3.1 Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Linagliptin DPP-4 Inhibitors Revenue by Application (2021-2032)
  11. 5.3.3 Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Linagliptin DPP-4 Inhibitors Sales by Region
  1. 6.1 Global Linagliptin DPP-4 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Linagliptin DPP-4 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Linagliptin DPP-4 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Linagliptin DPP-4 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Linagliptin DPP-4 Inhibitors Revenue by Region
  1. 7.1 Global Linagliptin DPP-4 Inhibitors Revenue by Region
  2. 7.1.1 Global Linagliptin DPP-4 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Linagliptin DPP-4 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Linagliptin DPP-4 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Linagliptin DPP-4 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Linagliptin DPP-4 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Linagliptin DPP-4 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Linagliptin DPP-4 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Linagliptin DPP-4 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yangzijiang Pharmaceutical Group
  2. 8.1.1 Yangzijiang Pharmaceutical Group Company Information
  3. 8.1.2 Yangzijiang Pharmaceutical Group Business Overview
  4. 8.1.3 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yangzijiang Pharmaceutical Group Linagliptin DPP-4 Inhibitors Product Portfolio
  6. 8.1.5 Yangzijiang Pharmaceutical Group Recent Developments
  7. 8.2 Cspc Holdings Company
  8. 8.2.1 Cspc Holdings Company Company Information
  9. 8.2.2 Cspc Holdings Company Business Overview
  10. 8.2.3 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cspc Holdings Company Linagliptin DPP-4 Inhibitors Product Portfolio
  12. 8.2.5 Cspc Holdings Company Recent Developments
  13. 8.3 MINSHENG PHARMACEUTICAL
  14. 8.3.1 MINSHENG PHARMACEUTICAL Company Information
  15. 8.3.2 MINSHENG PHARMACEUTICAL Business Overview
  16. 8.3.3 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 MINSHENG PHARMACEUTICAL Linagliptin DPP-4 Inhibitors Product Portfolio
  18. 8.3.5 MINSHENG PHARMACEUTICAL Recent Developments
  19. 8.4 Shandong Lukang Pharmaceutical
  20. 8.4.1 Shandong Lukang Pharmaceutical Company Information
  21. 8.4.2 Shandong Lukang Pharmaceutical Business Overview
  22. 8.4.3 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shandong Lukang Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  24. 8.4.5 Shandong Lukang Pharmaceutical Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Linagliptin DPP-4 Inhibitors Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Sichuan Kelun Pharmaceutical
  32. 8.6.1 Sichuan Kelun Pharmaceutical Company Information
  33. 8.6.2 Sichuan Kelun Pharmaceutical Business Overview
  34. 8.6.3 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sichuan Kelun Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  36. 8.6.5 Sichuan Kelun Pharmaceutical Recent Developments
  37. 8.7 China Resources Shuanghe Pharmaceutical
  38. 8.7.1 China Resources Shuanghe Pharmaceutical Company Information
  39. 8.7.2 China Resources Shuanghe Pharmaceutical Business Overview
  40. 8.7.3 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 China Resources Shuanghe Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  42. 8.7.5 China Resources Shuanghe Pharmaceutical Recent Developments
  43. 8.8 Huahai Pharmaceutical
  44. 8.8.1 Huahai Pharmaceutical Company Information
  45. 8.8.2 Huahai Pharmaceutical Business Overview
  46. 8.8.3 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Huahai Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  48. 8.8.5 Huahai Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Deyuan Pharmaceutical
  50. 8.9.1 Jiangsu Deyuan Pharmaceutical Company Information
  51. 8.9.2 Jiangsu Deyuan Pharmaceutical Business Overview
  52. 8.9.3 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Deyuan Pharmaceutical Linagliptin DPP-4 Inhibitors Product Portfolio
  54. 8.9.5 Jiangsu Deyuan Pharmaceutical Recent Developments
  55. 8.10 Chengda Pharmaceuticals
  56. 8.10.1 Chengda Pharmaceuticals Company Information
  57. 8.10.2 Chengda Pharmaceuticals Business Overview
  58. 8.10.3 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Chengda Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio
  60. 8.10.5 Chengda Pharmaceuticals Recent Developments
  61. 8.11 Zydus
  62. 8.11.1 Zydus Company Information
  63. 8.11.2 Zydus Business Overview
  64. 8.11.3 Zydus Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Zydus Linagliptin DPP-4 Inhibitors Product Portfolio
  66. 8.11.5 Zydus Recent Developments
  67. 8.12 Torrent Pharmaceuticals
  68. 8.12.1 Torrent Pharmaceuticals Company Information
  69. 8.12.2 Torrent Pharmaceuticals Business Overview
  70. 8.12.3 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Torrent Pharmaceuticals Linagliptin DPP-4 Inhibitors Product Portfolio
  72. 8.12.5 Torrent Pharmaceuticals Recent Developments
  73. 8.13 Mankind Pharma
  74. 8.13.1 Mankind Pharma Company Information
  75. 8.13.2 Mankind Pharma Business Overview
  76. 8.13.3 Mankind Pharma Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mankind Pharma Linagliptin DPP-4 Inhibitors Product Portfolio
  78. 8.13.5 Mankind Pharma Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Linagliptin DPP-4 Inhibitors Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 Alkem Labs
  86. 8.15.1 Alkem Labs Company Information
  87. 8.15.2 Alkem Labs Business Overview
  88. 8.15.3 Alkem Labs Linagliptin DPP-4 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Alkem Labs Linagliptin DPP-4 Inhibitors Product Portfolio
  90. 8.15.5 Alkem Labs Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Linagliptin DPP-4 Inhibitors Value Chain Analysis
  2. 9.1.1 Linagliptin DPP-4 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Linagliptin DPP-4 Inhibitors Production Mode & Process
  6. 9.2 Linagliptin DPP-4 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Linagliptin DPP-4 Inhibitors Distributors
  9. 9.2.3 Linagliptin DPP-4 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst